Why is AbbVie stock down today?

Traders Union
All News
Financial News
AbbVie slides 2.39% today to $219.98

Highlights

AbbVie's Phase 1 obesity drug ABBV-295 delivered promising weight loss and safety results, strengthening its pipeline prospects.
Dividend strength continues with quarterly payouts near $1.73 per share, as management compensation rises despite broader share price weakness.
ABBV trades below near-term resistance amid intraday selling, but weekly technicals signal a high probability of rebound toward $231.89–$240.78.

Growth optimism muted by sustained selling pressure in shares

AbbVie reported encouraging results from a Phase 1 trial of ABBV-295, a long-acting amylin analog targeting obesity, which showed promising weight loss and a favorable safety profile. The company also updated its ongoing Phase 1 dosing study of risankizumab to improve administration flexibility for its immunology franchise, while Skyrizi and Rinvoq therapies were cited as key growth drivers. A strong dividend policy continued with recent quarterly dividends around $1.73 per share and annual payouts over $6.90, and CEO Robert Michael received a compensation increase in 2025, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees rising concerns around ABBV’s price action. He notes the stock trades below both its SMA-20 and SMA-50 despite encouraging Phase 1 trial news and a consistent dividend. Technicals show mixed momentum, with RSI and several oscillators flagging oversold conditions, while underlying long-term support persists above the SMA-200. Near-term resistance is pressuring recovery attempts, and failed bullish attempts after gap opens highlight weak sentiment. "With high intraday volatility and sellers dominating below $225, ABBV remains at risk of deeper correction if long-term support levels are breached."

Viktoras Karapetjanc, expert at Traders Union, believes ABBV’s bullish structure remains intact. He notes solid fundamentals, including promising obesity drug data and robust dividend increases. The analyst highlights key weekly indicators flashing further growth potential and limited downside risk. Karapetjanc sees consolidation as an opportunity rather than a threat. "I expect further upside as strong fundamentals and positive momentum set the stage for ABBV to break above resistance and retest recent highs."

Intraday volatility contrasts oversold signals and longer-term support

ABBV is trading at $219.98, below the SMA-20 ($229.28) and SMA-50 ($224.81), but above the SMA-200 ($214.42). This places the price under short- and medium-term resistance, while the long-term trend still shows underlying support. The nearest dynamic support is around the Ichimoku Kijun level at $220.69. If the price recovers, resistance is expected near the SMA-50 and $225 round level. Momentum signals are mixed. MACD on D1 and W1 is in "Strong Buy," but ADX readings are neutral, indicating trend weakness. Daily RSI is in "Sell" territory, while Stoch RSI, CCI, and BBP all reflect oversold conditions and strong seller dominance intraday. AO is neutral and does not reinforce the current downtrend. The stock opened slightly higher ($226.89 vs. prior close $225.37), creating a small upward gap. After the open, the price quickly retreated and is now trading near the day's low ($221.29 – $228.62 range), with high intraday volatility. The tone is pressured lower, as sellers took control after the initial gap up. This intraday weakness contrasts with the underlying bullish momentum on longer timeframes, highlighting a clear divergence among technical signals.

Earlier, analysts noted that AbbVie was maintaining a generally bullish structure across timeframes despite exhibiting mixed technical momentum and periods of consolidation. The latest price action, now confronting both medium-term resistance and short-term seller dominance amid positive drug trial updates, suggests traders should closely monitor support near $220.69 and $214.42 as a decisive break below these levels could alter the longer-term upside scenario.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.